BJDX Latest Report

Key Financial Data

1. Bluejay Diagnostics's total operating revenue was -14,846,444 yuan as of December 31, 2024, an improvement from -23,867,224 yuan in 2023, with a decrease of 37.77%. This improvement indicates a rebound in the company's revenue, albeit still in a loss-making state.

2. The revenue rebound may be attributed to the increase in overseas customers for its antibody discovery business, resulting in a rapid growth in sales revenue, as well as a significant increase in the number of antibody molecules transferred externally, maintaining a high gross margin.

3. The reduction in research and development expenses also provides room for the company's performance improvement, with an estimated 30.1% to 34.3% decrease in R&D expenses in 2024.

4. The company's continuously growing gene-editing animal model business further drives revenue growth.

Peer Comparison

1. Industry-wide analysis: The overall market demand for medical devices is gradually recovering, especially after the pandemic, with many companies in the industry reporting revenue growth. As a part of the industry, BJDX may benefit from this trend.

2. Peer evaluation analysis: Compared to peers, BJDX's operating revenue is still negative, indicating pressure in the competition, although revenue has improved, further market share expansion and cost control are needed to achieve profitability.

Summary

Bluejay Diagnostics' operating revenue improved in 2024, reflecting the company's gradual recovery in the market, mainly due to the growth of its antibody discovery business and the reduction in R&D expenses. However, the negative revenue indicates that the company still needs to make efforts in the competition.

Opportunities

1. The increase in overseas customers for its antibody discovery business provides a new revenue growth point for the company.

2. The reduction in R&D expenses provides more funds for the company to expand the market and innovate products.

3. The overall recovery of the industry demand may bring more market opportunities for the company.

Risks

1. The price pressure on high-value consumables may affect the sales of Bluejay Diagnostics' high-priced products.

2. The rise of low- and medium-end domestic medical devices may put pressure on the company's market share.

3. Innovative medical devices face higher value verification requirements, which may limit the company's layout in the high-end market.